142 completed, 52 unknown, 41 terminated, 24 recruiting. 295 Phase 2, 53 Phase 3, 51 Phase 1.
Follow Shock: new trials by email Literature Review of Shock trials Research Report on Shock
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulopathy • Sivelestat intravenous infusion, NaCl intravenous infusion - Septic Shock, Coagulopathy | Phase 2 | Not yet recruiting | University Hospital, Strasbourg, France | 120 | 2027-08-01 | 2026-08-20 |
| Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp Dexamethasone - Uveal Melanoma, Metastatic | Phase 2 | Not yet recruiting | University of California, San Diego | 34 | 2026-11-01 | 2026-09-03 |
| Pre-emptive Anakinra for Cytokine Event Reduction Anakinra (Kineret®) - B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy | Phase 1 / Phase 2 | Withdrawn | Kevin McNerney | 2026-10-01 | 2026-08-13 | |
| CORTISHOCK-P: Trial of Corticosteroids in Inflammation-Enriched Heart Failure Cardiogenic Shock Methylprednisone, Standard of Care (SOC) - Cardiogenic Shock, Heart Failure | Phase 2 | Not yet recruiting | Brigham and Women's Hospital | 30 | 2026-10-01 | 2026-08-13 |
| Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic Shock istaroxime, placebo - Cardiogenic Shock | Phase 2 / Phase 3 | Recruiting | Seismic Pharmaceuticals Operations LLC | 600 | 2026-09-09 | 2026-09-23 |
| Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Cytokine Release Syndrome, Recurrent Multiple Myeloma | Phase 2 | Recruiting | Naresh Bumma | 35 | 2026-07-17 | 2026-10-06 |
| NAI for Sepsis With Persistent Lymphopenia Nogapendekin alfa inbakicept (NAI), Standard of Care (SOC) - Sepsis, Septic Shock | Phase 2 | Not yet recruiting | ImmunityBio, Inc. | 50 | 2026-07-06 | 2026-05-11 |
| Adjunctive Fludrocortisone in Septic Shock Fludrocortisone 100 mcg daily, Placebo - Sepsis, Septic Shock | Phase 2 | Recruiting | Chinese University of Hong Kong | 32 | 2026-04-01 | 2026-06-02 |
| POCUS-Guided Esmolol in Septic Shock: A Pilot RCT Esmolol - Septic Shock | Phase 1 / Phase 2 | Not yet recruiting | John Basmaji | 100 | 2026-01-15 | 2026-01-06 |
| Early Methylene Blue in the Microhemodynamics of Septic Patients Methylene blue infusion - Septic Shock, Hypoperfusion | Phase 2 / Phase 3 | Recruiting | Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva | 50 | 2026-01-09 | 2026-03-27 |
| Point-of-Care AI Assistance and Critical Care Outcomes: A Randomized Trial Point-of-care large language model decision support (ChatGPT-5) - Critical Illness, Sepsis | Phase 1 / Phase 2 | Not yet recruiting | MetroWest Artificial Intelligence Research Workgroup | 1000 | 2026-01-01 | 2025-12-18 |
| Sevoflurane Sedation in Patients With Septic Shock Sevoflurane, Control Group - Shock, Septic | Phase 2 | Not yet recruiting | University of Zurich | 153 | 2026-01-01 | 2025-04-01 |
| NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) Talikabtagene Autoleucel - Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma | Phase 2 / Phase 3 | Recruiting | Health Institutes of Turkey | 40 | 2025-09-11 | 2026-03-30 |
| A Comparative Study Between Dexmedetomidine Versus Methylprednisolone on Induced Inflammatory Response in Patients Undergoing On-pump CABG Normal saline, Dexmedetomidine, Methylprednisolone - Coronary Artery Disease, Systemic Inflammatory Response Syndrome | Phase 1 / Phase 2 | Unknown | Ain Shams University | 60 | 2025-09-01 | 2025-08-06 |
| A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma Siltuximab - CRS - Cytokine Release Syndrome, Myeloma | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-08-10 | 2025-08-06 |
| A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care. AK1967 (Invobenitug also known as Procizumab), Placebo - Shock, Cardiogenic | Phase 1 / Phase 2 | Recruiting | 4TEEN4 Pharmaceuticals GmbH | 90 | 2025-07-13 | 2026-09-14 |
| Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System Cardiohelp device (VA-ECMO), Heparin, Bivalirudin - Heart Failure, Cardiogenic Shock | Phase 2 | Recruiting | Stanford University | 50 | 2025-04-15 | 2026-08-10 |
| Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma Elranatamab injection - Refractory Multiple Myeloma | Phase 2 | Recruiting | Ontario Clinical Oncology Group (OCOG) | 40 | 2025-03-28 | 2026-09-28 |
| Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL Obinutuzumab, Glofitamab, Gemcitabine - Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma | Phase 2 | Recruiting | Hoffmann-La Roche | 130 | 2025-03-05 | 2026-10-09 |
| Pulse Study: Peripheral Use of Low-dose Vasopressors for Safety and Efficacy in the Intensive Care Unit Experiemental: Peripheral Venous Catheter - Shock, Peripheral Venous Catheterization | Phase 2 | Recruiting | Kingston Health Sciences Centre | 50 | 2025-02-03 | 2025-04-09 |
Showing 20 of 295. Sign in to see all of them.
Shock, Septic (147) · Sepsis (91) · Cytokine Release Syndrome (64) · COVID-19 (41) · Systemic Inflammatory Response Syndrome (24) · Shock, Cardiogenic (18) · Shock, Hemorrhagic (16) · Inflammation (15) · Multiple Organ Failure (15) · Respiratory Distress Syndrome (15) · Wounds and Injuries (15) · Coronavirus Infections (11) · Hemorrhage (11) · Acute Kidney Injury (10)
Pathological Conditions, Signs and Symptoms (295) · Pathologic Processes (292) · Inflammation (221) · Systemic Inflammatory Response Syndrome (210) · Infections (199) · Sepsis (67) · Respiratory Tract Diseases (52) · Lung Diseases (50) · Virus Diseases (48) · RNA Virus Infections (47) · Respiratory Tract Infections (45) · Cardiovascular Diseases (44) · Coronaviridae Infections (43) · Nidovirales Infections (43)
Saline Solution (24) · Sodium Chloride (19) · Standard of Care (15) · Ascorbic Acid (12) · esmolol (10) · Hydrocortisone (9) · Thiamine (9) · Methylene Blue (7) · Norepinephrine (6) · Vasopressins (6) · tocilizumab (6) · Dobutamine (5) · Heparin (5) · Interleukin 1 Receptor Antagonist Protein (5) · Ringer's Lactate (5)
Beth Israel Deaconess Medical Center (7) · University of Roma La Sapienza (6) · Dascena (5) · AstraZeneca (3) · Austin Health (3) · Erasmus Medical Center (3) · Ferring Pharmaceuticals (3) · King Abdul Aziz Specialist Hospital (3) · Mahidol University (3) · Mansoura University (3) · Ottawa Hospital Research Institute (3) · Sangart (3) · University of Colorado, Denver (3) · University of Manitoba (3) · Zhujiang Hospital (3)
United States (94) · France (25) · Canada (20) · Germany (18) · Italy (18) · Belgium (14) · Denmark (13) · Egypt (13) · Netherlands (13) · Spain (13) · Australia (12) · Brazil (12) · China (12) · Israel (9) · India (8)
Andrea Morelli, MD (5) · Michael W Donnino, MD (4) · Eric Bellissant, MD, PhD (3) · Karim Brohi, MD (3) · Ritankar Das, MSc (3) · Wayne Dankner, MD (3) · Andrea Morelli, M.D. (2) · Christian Hassager, MD, DMSc (2) · Joaquin Espinosa, PhD (2) · Justin Lindemann, MD (2) · Lauralyn McIntyre, MD (2) · Michael C Reade, MBBS DPhil (2) · Ryan Zarychanski, MD MSc (2)
PMID 23001587, PMID 24484547, PMID 26220293, PMID 26903338, PMID 36915146, PMID 10415784, PMID 10722036, PMID 1138591, PMID 11502226, PMID 11588440, PMID 12454520, PMID 12500513, PMID 12519925, PMID 12545007, PMID 12563677, PMID 12700374, PMID 14719037, PMID 14759425, PMID 15103422, PMID 15231405, PMID 15663512, PMID 1607900, PMID 16134000, PMID 16134766, PMID 16483293, PMID 16507156, PMID 16553654, PMID 16570523, PMID 16616623, PMID 17019126, PMID 17181919, PMID 17617901, PMID 17698886, PMID 17720019, PMID 18097874, PMID 18353115, PMID 18477932, PMID 18805742, PMID 19017409, PMID 19048243, PMID 19114895, PMID 19114908, PMID 19280394, PMID 19397687, PMID 19453649, PMID 19534818, PMID 19664253, PMID 19998041, PMID 20332511, PMID 20646908
2018 (3), 2014 (2), 2015 (2), 2017 (2), 2019 (2), 2005 (1), 2016 (1), 2023 (1), K08HD052885 (1), K12TR005104 (1), K23HL096054 (1), K23HL128814 (1), P30CA016672 (1), R01DK133142 (1), R44AA030000 (1)